SB3944, titled the Women’s Heart Health Expansion Act of 2026, would reauthorize and expand the WISEWOMAN program under the Public Health Service Act. The bill allows the Centers for Disease Control and Prevention to award supplemental grants to existing breast and cervical cancer screening grantees to provide additional preventive services for women, including screenings for blood pressure, cholesterol, obesity, and other cardiovascular risk factors, along with evidence-based health education and referrals for treatment and follow-up care. It also broadens eligibility to include women already served under the current program as well as other high-risk women who meet criteria set by the Secretary of Health and Human Services.
Impact
The bill would amend Section 1509 of the Public Health Service Act and authorize $250 million in appropriations for fiscal years 2027 through 2031. In practical terms, it would expand federal support for preventive women’s health services, especially cardiovascular screening and education, through CDC-administered grants and related provider networks. It also directs the Comptroller General to conduct a GAO study on the program’s reach, trends in participation, barriers to access, and cost-effectiveness, which could influence future oversight and reauthorization decisions.
Sentiment
The available context suggests generally favorable treatment of the bill. It was introduced with bipartisan sponsorship by Senators Alsobrooks and Britt, and it advanced to the Senate Committee on Health, Education, Labor, and Pensions, where hearings were held. The bill’s focus on women’s heart health, prevention, and early detection aligns with broadly supported public health goals, and there is no recorded vote or transcript showing organized opposition in the provided materials.
Contention
No specific committee debate or vote record is provided, so there are no documented points of contention in the available context. Potential areas of discussion, however, may include the size of the proposed authorization, how eligibility would be defined for “high-risk” women, whether the program should remain tied to breast and cervical cancer screening grantees, and how to measure cost-effectiveness and access barriers. Any disagreement would likely center on funding levels, program scope, and administrative discretion rather than the underlying public health purpose.